GlassScriptPhysician profile
Michael B Lakow
NPI 1588603088
$7,150.39
in general payments reported to CMS, 2019-2025
22 companies · $785 in 2025
The $785 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,394 · 2020: $914 · 2021: $872 · 2022: $950 · 2023: $1,153 · 2024: $1,083 · 2025: $785.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,004 · Education: $17.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,003.94 |
| Education | $17.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,295.23 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $1,239.86 | 2019-2025 | |
| Amgen INC. | $1,184.47 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $918.90 | 2019-2025 | Jardiance |
| Pfizer INC. | $571.88 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $380.69 | 2019-2025 | Camzyos, Eliquis |
| Sanofi-Aventis U.S. LLC | $260.48 | 2019-2024 | |
| Heartflow, INC. | $203.22 | 2023-2025 | Ffrct |
| Merck Sharp & Dohme LLC | $182.46 | 2022-2024 | Verquvo |
| Abbott Laboratories | $156.17 | 2020-2025 | Aveir, Jot Dx |
| Kestra Medical Technology Services, INC. | $145.07 | 2023-2025 | Assure Wcd |
| Boston Scientific Corporation | $134.30 | 2019-2025 | Watchman Flx |
| Medtronic Vascular, INC. | $125.61 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $76.67 | 2020-2023 | Farxiga |
| Cvrx, INC. | $73.80 | 2023-2025 | Barostim Neo System |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $56.07 | 2024 | Arcalyst |
| Amarin Pharma, INC. | $35.91 | 2019-2021 | |
| Acutus Medical, INC. | $26.49 | 2022 | |
| Abiomed | $25.22 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $19.65 | 2024 | Lifevest |
| Philips North America LLC | $19.15 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Biosense Webster, INC. | $19.09 | 2024 | Carto 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lakow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.